Wells Fargo assumed coverage of Alaunos Therapeutics with an Overweight rating and $3 price target, with no changes made to rating or target.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on TCRT: